ArticlePharmaceutics2022

Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation.

Dusan Ruzic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.